Shots:

• The P-III COVE study demonstrated 94.1% efficacy against COVID-19 and 100% efficacy against severe COVID-19. The vaccine was well tolerated with no serious safety concerns identified to date
• Moderna plans to submit an EUA to the FDA & an application for CMA with the EMA and to progress with the rolling reviews- which have already been initiated with international regulatory agencies
• The FDA has told Company to expect VRBPAC meeting for mRNA-1273 on Dec 17- 2020. The Company will submit data from the P-III COVE study to a peer-reviewed publication

 ­ Ref: Moderna | Image: Moderna